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Metastases to the heart and pericardium are rare but more common than primary cardiac tumours and are
generally associated with a rather poor prognosis. Most cases are clinically silent and are undiagnosed in vivo until
the autopsy. We present a female patient with a 27-year-old history of an operated primary breast cancer who was
presented with dyspnoea, paroxysmal nocturnal dyspnoea and orthopnoea. The clinical signs and symptoms
aroused suspicion of congestive heart failure. However, the cardiac metastases were detected during a routine
cardiologic evaluation and confirmed with computed tomography imaging. Additionally, this paper outlines the
pathophysiology of molecular and clinical mechanisms involved in the metastatic spreading, clinical presentation,
diagnostic procedures and treatment of heart metastases. The present case demonstrates that a complete surgical
resection and systemic chemotherapy may result in a favourable outcome for many years. However, a lifelong
medical follow-up, with the purpose of a detection of metastases, is highly recommended. We strongly call the
attention of clinicians to the fact that during the follow-up of all cancer patients, such heart failure may be a
harbinger of the secondary heart involvement.
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Metastases to the heart assume greater diagnostic and
therapeutic importance as the incidence of different can-
cer types rises. The condition was first described by
Theophy Boneti in 1700 [1]. Primary tumours of the
heart are rare, occurring at a frequency of <0.02% in dif-
ferent autopsy series [2]. However, secondary or meta-
static tumours of the heart are more common than
primary tumours [3] and patients may present with* Correspondence: darko.katalinic@kbc-zagreb.hr
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reproduction in any medium, provided the orvarious cardiac symptoms. Common primary tumours to
metastasise to the heart are mediastinal tumours, lung
cancer, melanoma, breast cancer and esophageal cancer
[4]. Intracavitary growth of secondary heart tumours,
however, is quite unusual. Therefore, despite their fre-
quency, metastases to the heart rarely gain clinical atten-
tion. The signs of cardiac involvement are often
overlooked, since the symptoms of a metastatic disease
prevail. We present a case of breast cancer with symp-
tomatic heart metastases and heart chambers involve-
ment 27 years after mastectomy and discuss the
pathophysiology of molecular mechanisms of cardiacl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnostic procedures and treatment.
Case presentation
The patient’s past medical history was significant for a
right-sided total mastectomy for carcinoma in 1984 (PHD:
Adenocarcinoma of the breast) (Figure 1A and 1B). The pa-
tient was staged as T2N0M0. At that time, she had no radi-
ation or chemotherapy. All lymph nodes were negative. In
1992, the patient was diagnosed with lung metastases and
treated with CMF regimen (cyclophosphamide, methotrex-
ate and fluorouracil), with a partial tumour regression. In
1995, she underwent the ablation of solitary metastasis in
the left lung lobe (PHD: Metastatic adenocarcinoma of the
breast). In 1999, a complete clinical re-evaluation was madeFigure 1 Histopathological evaluation. Hematoxylin and eosin (HE) histo
clusters of atypical, polymorphic epithelial cells (image A, high-power phot
partially necrotic (image B, low-power photomicrograph, original magnifica
tumour cells stained positive for estrogene receptors (ER) (image C, low-po
receptors (image D, low-power photomicrograph, original magnification, ×since the hymoptysis and a solitary metastatic tumour in
the distal left lung were diagnosed. She underwent a left-
sided pulmectomy and mediastinal lymphadenectomy
(PHD: Metastatic adenocarcinoma of the breast) with good
clinical outcome and the disease was stabile for the follow-
ing 6 years. In 2005, at regular oncologic follow-up, the pa-
tient was diagnosed with a tumour formation under the left
scapula which was surgically removed (PHD: Metastatic
adenocarcinoma of the breast, ER+, HER-2/neu +++)
(Figure 1C and 1D). After that, she was treated with ana-
strosol and trastuzumab with regular medical follow-up
and she felt quite well.
In 2011, 27 years after mastectomy, a 64-year-old white
woman was admitted to our hospital with a 2-week history
of shortness of breath, dyspnoea, paroxysmal nocturnallogic analysis revealed a highly cellular malignant tumour with solid
omicrograph, original magnification, ×400; HE stain). The tumour was
tion, ×100; HE stain). Immunohistochemical study shows that the
wer photomicrograph, original magnification, ×200) and HER-2/neu
200) consistent with diagnosis of breast adenocarcinoma.
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presentation aroused suspicion of a congestive heart fail-
ure. The Karnofsky’s index of performance status (KPS)
was 20% and the Eastern Cooperative Oncology Group
Performance Status Scale (ECOG PS) was grade 4. On ad-
mission, the patient was afebrile and in a moderate degree
of respiratory distress. There was no clinical or laboratory
evidence for any kind of inflammation or pulmonary em-
bolism. Her pulse was 140 beats per minute and regular,
and her blood pressure was 130/90 mmHg. The heart
sounds were distant and faint, there were no heart mur-
murs. Chest radiography revealed an increase in cardiac
silhouette and the lung congestion. The electrocardiogram
showed sinus tachycardia and low voltage without other
abnormalities. All cardiac enzymes were negative.
However, the high values of carbohydrate antigen 15–3
(Ca 15–3) (335.2 kIU/L, normal rate <25) and carcinoem-
bryonic antigen (CEA) (380.8 μg/L, normal rate <3.4) sug-
gested clinical relapse. Two-dimensional transthoracic
echocardiography (2D-TTE) revealed cardiac involvement
with metastatic tumour mass (Figure 2). A contrast-Figure 2 Echocardiographic evaluation. Four-chamber 2-dimensional tra
(2.3×1.1 cm), which infiltrated pericardium and myocardium (predominantl
propagation (arrows).enhanced multislice computed tomography (MSCT) of
the chest confirmed and demonstrated a large metastatic
mass that involves predominantly the pericardium and the
left ventricle with the extension into the left atrium
(Figure 3A-3E). The patient was treated with corticoster-
oids, amynophilline, digitalis, beta-adrenergic antagonists,
analgetics, low-molecular-weight heparin and oxygenation.
The palliative radiation therapy was initiated, but because
of patient’s severe general condition, a total dose of only 6
Gy/day was delivered as a palliative thoracic radiotherapy.
Unfortunately, soon after hospital admission, the patient
died. The immediate cause of death was cardiorespiratory
arrest due to massive involvement of the heart by meta-
static malignancy.
Discussion
Malignant tumours metastasizing to the heart are one of
the least investigated topics in clinical and experimental
oncology. In the past, the low incidence of cancer to the
heart has been explained on the theory that the heart
was not receptive to tumour cells. Prichard mentionednsthoracic echocardiogram shows a large, irregular metastatic mass
y anteroapical and lateral walls of the left ventricle) with intracavitary
Figure 3 Radiological evaluation. Contrast-enhanced axial (Figures 3A-3C), coronal (Figure 3D) and sagittal (Figure 3E) multislice computed
tomography scan of the chest revealed massive, predominantly necrotic metastatic tumour mass (13×10 cm in size on axial view) with pericardial
and heart involvement (arrows). The tumour was partially necrotic and infiltrated the thoracic aorta and the pulmonary trunk with extension into
the left atrium.
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heart muscle, and the rapid blood flow as factors
accounting for the low incidence [5]. Other authors con-
sidered that the low incidence was more likely the result
of inadequate observation. Until the 1960s, primary and
especially secondary cardiac tumours were merely a
curiosity and the diagnosis was academic. Generally,
they have devastating consequences given that they in-
volve such an important organ and present in very
subtle ways causing a subsequent delay in clinical diag-
nosis. In the past two decades, imaging has improved
detection, with 2D-TTE, 2-dimensional transesophageal
echocardiography (2D-TEE), computed tomography
(CT) and magnetic resonance imaging (MRI) being the
mainstay of clinical evaluation [6]. Because of its easy
availability, 2D-TTE, 2D-TEE and radiology procedures
such as CT or MRI are complementary techniques, and
are all used in the evaluation of cardiac deposits. Withthe gradual improvement in surgery, chemotherapy,
radiotherapy, biotherapy and molecular targeted therapy,
life-threatening sites of metastases are more commonly
receiving intensive local therapy for palliation. Such
tumours are frequently highly responsive to radiotherapy
or chemotherapy, and premortem diagnosis may be crit-
ical in the clinical management. Although no malignant
tumours are known which diffuse preferentially to the
heart, some do involve the heart more often than others,
for instance lung cancer, breast and esophageal cancer,
lymphoproliferative malignancies, as well as melanoma
[5,7-12]. Metastasis is cancer’s most deadly aspect and it
is affected by several interconnected processes. There-
fore, tumour’s ability to spread to the heart tissue
depends on many different factors, not only the molecu-
lar, biological and pathophysiological characteristics of
the primary tumour, but also the specific structural and
functional characteristics of the heart [5].
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pathways and cascades: from molecular to clinical aspects
Although primary cardiac tumours are extremely rare
(different postmortem studies reported rates between
0.001% and 0.28%), secondary tumours are not, and the
heart can be metastasised by any sort of malignancy
[13,14]. Only tumours of the central nervous system have
not been proven to develop heart metastases. The exact
incidence of cardiac metastases is unknown. Indeed, sec-
ondary deposits are considered rare, but when sought for,
the incidence seems to be not as low as expected [15] and
they exist usually in the setting of a widely disseminated
disease [12]. Reflecting the age distribution, heart metasta-
ses predominantly occur in patients between the sixth and
eighth decades of life and there is no gender preference.
They were found in 1.23% of 12,485 consecutive autopsies,
compared with a 0.056% prevalence of primary cardiac
tumours [12]. In autopsies at which a malignant neoplasm
was diagnosed, cardiac metastases were found in 9.7% to
10.7% of cases [4,16,17]. According to Bussani et al., the
highest rates of heart metastasis were found in patients
diagnosed with pleural mesothelioma (48.4%), melanoma
(27.8%), lung cancer (21%) and breast cancer (15.5%).
High rates have also been found in patients with ovarian
cancer (10.3%) and lymphoproliferative malignancies
(9.4%). About two-thirds of all heart metastases involved
the pericardium and only one-third the epicardium or the
myocardium [18]. Some tumours colonize a wide variety
of organs and the first site encountered will be the most
common site of metastatic formation. Others are more se-
lective, they bypass some organs and selectively colonize
specific distal tissues. Interestingly, for reasons which are
not clear, melanoma has a particular predilection for
metastasising to the heart and brain and a half of all cases
of disseminated melanoma patients will have cardiac
deposits at necropsy [19]. However, breast cancer primarily
metastasizes to the bone, lungs, regional lymph nodes, liver
and brain, with the most common site being the bone.
In 1889, Stephen Paget noticed that metastases in
breast cancer were not random. He postulated ‘seed and
soil’ hypothesis claiming that a metastatic cells arose
from the proliferation of a few tumour cells (the seeds)
in the favourable tissue environment provided by certain
organs (the soil) [20]. According to the ‘seed and soil’
theory, it is difficult for cancer cells to survive outside
their region of origin, so in order to metastasize they
must find a location with similar characteristics [20]. For
instance, melanoma spreads to the brain, presumably be-
cause neural tissue and melanocytes arise from the same
cell line in the embryo. A few decades later, in 1928, op-
posite to Pageth’s opinion, James Ewing challenged the
‘seed and soil’ theory and proposed that metastasis
occurs purely by anatomic and mechanical routes [21].
Today, it is widely known that both Paget and Ewingwere right and that the two theories are not mutually ex-
clusive. Additionally, organ-specific anatomic considera-
tions also influence the metastatic process. These include
blood-flow patterns from the primary tumour and the
homing ability of cancer cells to certain tissues and organs.
Typical environmental barriers in a metastatic event in-
clude physical (a basement membrane - BM), chemical
(low pH, reactive oxygen species, hypoxia, and so on) and
biological (immune surveillance, inhibitory cytokines and
regulatory extra-cellular matrix peptides) components
[22]. During tumour invasion, malignant cells penetrate a
variety of extracellular matrices (ECM), including BMs
and interstitial stroma through multiple steps in the meta-
static cascade. To be completely successful, a tumour cell
must invade and degrade connective host tissue (invasion
of the primary tumour border - BM and the tissue sur-
rounding the tumour by the cell) and subsequently intra-
vasate (the bloodstream or lymph channels), survive the
transit into the new environment, arrest in distant vascular
bed, extravasate to a distant site (the tumour cell than
invades into the BM of the targeted tissue interstitium),
initiate a micrometastasis and proliferate to metastatic col-
ony [21,22]. The initial part of this cascade also known as
‘epithelial to mesenchymal transition’ (EMT) was first
conceived by Krug et al. in 1987 and described by Hay in
1995 [23,24]. It is defined as the switch from non-motile,
polarized epithelial cells to motile, non-polarized mesen-
chymal cells, with the potential to migrate from primary
tumour sites to distant tissues and organs, where they can
proliferate [23-25]. There are several EMT components,
and the most important are E-cadherin, N-cadherin, and
transforming growth factor-β (TGF-β) [26]. A ringleader
of EMT is a process named the ‘cadherin switch’, defined
by a decrease in E-cadherin, the component of adherent
junctions, and a simultaneous increase of mesenchymal
N-cadherin. This switch allows cells to lose adhesive affin-
ity for other surrounding cells and become more migra-
tory and invasive [26-29]. Another most potent inducer of
EMT is the TGF-β, a known pluripotent growth factor,
able to induce EMT in mammary and other cell types
[26,30,31]. As we know, the process of metastatic spread-
ing is a complex series of different steps. Malignant cells
break away from the primary tumour and degrade
proteins that make up the surrounding ECM, which sepa-
rates the tumour from adjoining tissue. Cell-ECM adhe-
sion, motility, and localised proteolysis are mediated
mainly by matrix metalloproteases (MMPs). The tumour
cell develops structures called invadopodia, which are
highly concentrated in several MMPs [32,33]. Therefore,
the degradation of ECM is facilitated by MMPs, and
tumour cells can move across tissues into nearby stroma.
ECM-tumour cell interactions play a critical role in each
of the events of the metastatic cascade. Interactions of the
breast cancer cells with integrins, fibronectin, tenascin C,
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proteoglycans can contribute to the metastatic process.
The ECM protein Tenascin C (TNC) is an adhesion-
modulating extracellular matrix glycoprotein and it is
upregulated in metastatic breast cancer. TNC is highly
expressed in tumour stroma and stimulates tumour-cell
proliferation. Endoglin is a cell-surface disulfide-linked
homodimeric glycoprotein which binds to integrins and is
a co-receptor for TGF-β. For instance, brain and heart-
metastatic breast-tumour cells also express endoglin in
large amounts [34,35]. Heparanase expressed by breast
cancer cells participates in angiogenesis and neovasculari-
sation by degrading the polysaccharide scaffold of the
endothelial BM, thereby releasing angiogenic growth fac-
tors from the ECM [36]. There are also several different
cell types critical for tumour growth. Gao et al. and Nolan
et al. demonstrated that endothelial progenitor cells are
critical for metastasis and angiogenesis [37,38]. Further-
more, the ablation of endothelial progenitor cells in the
bone marrow leads to a significant decrease in tumour
growth and vasculature development [39]. Metastatic
spreading is also mediated by numerous growth factors
and cytokines, operating through different cell signalling
pathways. To initiate transcriptional responses, these sig-
nalling molecules must enter the nucleus through the nu-
clear pore complex (NPC). The NPCs are made of
proteins named nucleoporins (Nups) and there are several
Nups that are often abnormal in cancer patients. Some of
them are Ribonucleic acid exports 1 (Rae1) linked to
breast cancer pathophysiology [40] and Nup88 which is
overexpressed in ovarian cancer [41] as well as in a broad
spectrum of sarcomas, lymphomas and mesotheliomas
[42,43]. The transport of different cytokines, transcription
factors (HER2, TGF-β, galectin-3, NF-κB and other), or
metastasis activators across the nuclear envelope com-
monly requires transporters (karyopherins) that bring
them to the nuclear pore. Finally, these molecules are
translocated into the nucleus, where they can bind to tar-
get genes to initiate transcription and consequently cell
migration and proliferation. For the metastasis to occur,
all steps in the metastatic cascade must take place. There-
fore, the blockade of any single step in the metastatic
pathway should slow down metastasis progression [44].
Heart metastases are usually small and multiple; infre-
quently, single large tumour lesions are also observed.
Clinically, they occur by four main routes: transcoelo-
mic, lymphatic, haematogenous and thru implantation.
Metastases may reach the heart via the hematogenous
or lymphatic route, or by direct or transvenous exten-
sion. Lymphatic spread is most important and tends to
give rise to pericardial metastases, while hematogenous
spread preferentially gives rise to myocardial metasta-
ses. Tumours such as the breast cancer, which develop
near the heart, may expand by direct extension into theheart tissue, but these tumours predominantly attain to
the heart by the lymphatics. Via mediastinal lymph
nodes, tumour cells intially invade the epicardial, and
then the myocardial lymphatic system [45]. As in our
case, secondary heart tumours that have partial or total
intracavitary growth are rare; when they do occur, they
are often accompanied by thrombosis [46-51].
The structure of the lymphatic system in the heart might
explain the low incidence of secondary deposits in the
heart compared with other tissues and organs [18]. As a
particularity of lymphatics in the heart, the flow in the
capillaries is high, determined by the effects of heart
pressure. If lymphatics are obstructed by tumour cells,
lymph will stagnate in the myocardial regions upstream of
the obstruction, and endocardial to epicardial drainage by
the lymphatics will be inhibited. This in turn leads to tis-
sue damage due to lymph stasis, and favours an increased
proliferation of neoplastic cells in undrained regions and
retrograde lymph flow, which might disseminate malig-
nant cells to the more internal parts. As a result of
increased pressure, the lymphatic wall may also break,
leading to interstitial tumour spread. The blockade of the
common lymphatic node by neoplastic cells coming from
metastasised mediastinum lymph nodes is a key event
leading to the formation of metastases. The penetration
into the myocardium is favoured by the stasis of the lymph
flow, and most importantly by the damage to the
epicardial plexus caused by the stasis in part, but also by
the direct effect of the tumor cells [18,52].
Interestingly, metastatic cell does not disseminate neces-
sarily from the primary tumour. The first step in this
process is metastasis to a ‘generalizing site’ such as lungs,
liver, and so on (primary level of dissemination). This key
disseminating site is the first filter encountered by blood-
borne or lymph-borne metastases once they are released
from the affected lymph nodes. For a given primary
tumour, more than one such key metastatic site may exist.
Dissemination of malignant cells then proceeds via sec-
ondary metastases from the generalising sites (secondary
level of dissemination) [53].
Finally, more recent molecular studies have shown that
some forms of malignant tumours, including breast can-
cer, arise from a small subset of cancer stem cells (CSCs),
which are often marked by the cell surface antigens
CD133, CD144 and CD24. These cells induce tumour for-
mation and are often resistant to conventional anticancer
treatments. The CSCs expresses specific repertoire of sur-
face markers, which allows their differential purification,
selectively endowed of tumorigenic capacity as opposed to
all other subsets. They sustain the growth of heteroge-
neous cancer tissues, which recreate the full repertoire of
tumour cell populations observed in the primary tumour,
and most importantly, they display the main functional
hallmarks: self-renewal and differentiation. However, the
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with respect to metastasis, has not been well-defined and
it has remained partially understood [54-57]. Obviously,
better understanding of CSCs as a fundamental compo-
nent of the metastatic cascade may lead to novel thera-
peutic strategies [58].
Clinical manifestations and diagnostic procedures
There is no strong correlation between the extent of car-
diac metastases and clinical symptomatology. Some
tumours, even with extensive spreading to the heart, pro-
duce no symptoms and become evident by incidental find-
ings. Usually, heart involvement is not noticed until after
death. In some retrospective studies, only about 10% of
patients who died of metastatic disease presented with
symptoms or signs related with heart failure [9,59]. The
symptomatology and clinical presentation vary, depending
more on location than on size and can be classified as
extracardiac (constitutional and mechanical), cardiac
(pericardial, myocardial and intracavitary) or combined.
Constitutional symptoms of pyrexia, arthralgias, rash and
so on are mostly caused as a result of cytokine release.
Mechanical symptoms (dyspnea, orthopnoea and chest
discomfort) result from compression of cardiac chambers
or coronary arteries or from pericardial irritation or tam-
ponade caused by growth or effusion/haemorrhage within
the pericardium. Myocardial symptoms are caused by
arrhythmias due to compression or encroachment on the
conduction system. Intracavitary symptoms are caused
due to secondary deposits that obstruct valvular function,
blood flow or combined, or to tumours that cause tumour
fragments to embolize into the systemic circulation or the
lungs [18,51]. Intracavitary symptoms may also vary with
body position, which can alter haemodynamics. Most
patients show symptoms of congestive heart failure,
superior vena caval obstruction or embolization [60].
According to the anatomic location of the tumour, some
special symptoms and physical findings can be grouped
together with regard to pericardial, myocardial and
endocardial/heart chamber involvement [61-71].
Pericardial involvement may occur alone or may be
associated with metastases elsewhere in the heart.
Intrathoracic growths, usually carcinoma of the breast
and lungs, may extend directly into the pericardium
where the tumour may further invade other parts of
the heart. The most feared complications are neoplastic
pericardial effusions which can be serous,
serosanguineous or bloody, and may lack
haemodynamic compromise. They may be mild
(and result in no symptoms; in cases of a slow increase
in pericardial fluid, the pericardium may stretch and
the pericardial effusion can remain asymptomatic for
some time) but they are commonly symptomatic andoften the first manifestation of a heart metastasis [61].
In all cases of a rapid increase in pericardial fluid,
cardiac tamponade can result and necessitate
immediate pericardiocentesis [4,8]. Slater et al. even
reported a case of constrictive pericarditis from
metastatic breast cancer to the pericardium [62].
Hypotension, dyspnea, venous congestion, peripheral
cyanosis, pulsus paradoxus and fall in QRS voltage are
all hallmarks of diagnosis. Chest X-ray may reveal an
increase in cardiac silhouette. The electrocardiogram
(ECG) may be helpful in demonstrating pericarditis,
but as Lamberta et al. concluded: ‘The
electrocardiographic changes illustrative of pericarditis
are minimal in subjects with malignancies of the
pericardium unless there is suifficient involvement’
[63]. Tumour-induced pericardial effusion and
pericardial masses can be best viewed by means of
2D-TTE and 2D-TEE imaging, CT scan, high resolution
CT and MRI. Moreover, the pericardiocentesis
specimen can be submitted to cytological analysis to
typify the tumour cells and help identify the primary
tumour origin.
Myocardial involvement may occur from encroachment
on the pericardium, or conduction system by secondary
deposits. Tumour tissue in the myocardial mass is
usually asymptomatic and does not produce any
characteristic ECG signs, but there are many
exceptions. Generally, the clinical pattern is
proportional to the degree of myocardial infiltration, or
related to the wall infiltration site. Whenever the right
heart is involved, the interventricular septum is likely
to share in the process, and the conduction system may
be compromised. Arrhythmias may occur, however,
without septal invasion, and they are important for
ante mortem diagnosis. Different ECG changes are
extremely common in cardiac metastasis and ECG has
been of some help [64,65]. Typical presentation
includes atrial flutter or fibrillation, premature beats
and paroxismal supraventricular and ventricular
arrhythmias (commonly tachycardias) conduction
disturbances and atrioventricular blocks [64]. Tumour
emboli occasionally plug a vessel and produce coronary
insufficiency, symptoms of angina pectoris or
myocardial infarction [3]. Association between tumour
infiltration of the heart and cardiac rupture has been
reported only in isolated cases. Metastases to the heart
may affect the muscle sufficiently to produce
congestive heart failure. Scott and Garvin concluded
that the development of congestive failure without
apparent cause in patients with malignant disease raises
the possibility of cardiac metastases. [8]. Ceardic
metastases may also cause T-wave changes, S-T
deviations and Q waves [9]. Displacement of the RS-T
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in all leads may also be found [66,67].
Heart chambers involvement is uncommon and the
symptoms of venous and intracardiac involvement are
often minimal in relation to the extensive involvement
seen. Tumour emboli reaching the chambers may
implant on the endocardium directly causing valvular
stenosis, valvular insufficiency or heart failure.
Murmurs typical of stenosis may be caused by
metastatic deposits and may change with position.
Syncope and sudden death have also been reported
[47,68]. Furthermore, intracavitary right-sided heart
metastases can lead to pulmonary embolism, and left-
sided heart metastases to systemic embolism [50,69,].
Most of the endocardial growths cause little disability
and, like most metastatic deposits of the heart, are
usually unexpected and incidental necropsy findings.
Endocardial metastases may also mimic bacterial
endocarditis which is relevant for differential diagnosis.
Tumour cells that infiltrate the lumen of a great vein
may initiate the deposition of fibrin upon them. The
fibrin, in turn, serves as a framework for continued
tumour growth. The thrombosis may also extend along
the vein to the heart chambers, hindering blood flow
and effective heart function. The left atrium may be
invaded from the extension of tumour thrombosis of
the pulmonary veins. 2D-TTE and 2D-TEE with CT or
MRI are valuable in delineating the presence or
absence of intracardiac tumour masses [6,50,69].
Nuclear medicine techniques previously employed to
detect secondary heart deposits include blood pool
imaging and gallium or thallium scintigraphy [70].
Positron-emission tomography computed tomography
([18F] FDG-PET/CT) has already been proven be more
accurate than CT in the evaluation of metastatic heart
tumours, especially in the follow-up of patients
previously treated with chemotherapy and/or
radiotherapy [71]. [18F]FDG-PET/CT, positron-
emission tomography MRI (PET-MRI) and 3-
dimensional echocardiography may have the advantage
of detecting the metastases in comparison with other
conventional imaging modalities [71-73].
Treatment
The pathophysiological and clinical aspects of cardiac
metastases are intriguing, but, whatever the treatment,
their clinical evolution is usually disappointing. In many
cases, secondary deposits manifest in patients with
advanced cancer disease, with the heart being involved in
the generalised cancer spread. Most patients will already
have undergone surgical treatment for the primary
tumour, or chemotherapy and/or radiation therapy. The
treatment of heart metastases depends on tumour originand patient’s general condition (correlation with Karnofsky
and ECOG performance scores), and may include different
systemic chemotherapy or palliation [51]. However, the
treatment is usually palliative because the prognosis is
poor, but radiation therapy can successfully palliate cardiac
metastases while preserving quality of life. In the specific
cases where secondary cardiac involvement leads to the
initial diagnosis of primary tumour, or is the first evidence
of metastatic recurrence, aggressive management may re-
sult in long-term survival [18,74]. Surgery would be only
considered in patients whose primary tumour is under
control and who have a significant disease-free interval.
Surgery is also indicated in exceptional cases of solitary
intracavitary growth, leading to obliteration of heart
chambers or valve obstruction, and the patient appears to
have a good prognosis [75]. However, in both cases, the
postoperative mortality is significant [76,77]. This poor
prognosis points to the importance of selecting an appro-
priate mode of therapy, taking into consideration each pa-
tient individually [78].
Conclusion
Progress in cancer biology has expanded our understanding
of the molecular and cellular mechanisms of cancer devel-
opment, metastatic spreading to the heart and other tissues,
as well as resistance of cancer cells to chemotherapy and
radiotherapy. This manuscript has reviewed some of the
key pathways that have been shown to play an important
role in the process of breast cancer spreading to the heart
and different diagnostic and treatment modalities. However,
breast cancer and other malignant tumours, as a result of
their genomic instability, have tremendous redundancy in
their ability to maintain growth and to spread into sur-
rounding tissues and distant organs. As such, this remark-
able level of complexity makes successful treatment of
breast cancer metastases all the more challenging. Accord-
ing to some reports, an average survival period after the
diagnosis of cardiac metastases has been approximately 5.5
months [77]. Obviously, it is very important to know that
in cancer patients with symptoms of heart failure, meta-
static cardiac deposits must always be considered in the
differential diagnosis, even in the subjects with a distant
positive medical history. Clinicians should be alert to the
possibility of cardiac metastasis in a patient with and even
without clinical symptoms. 2D-TTE and 2D-TEE, which
are easy, fast and sensitive techniques for detection of
cardiac metastasis, and CT, MRI, [18F]FDG-PET/CT and
PET-MRI as confirming methods should always be per-
formed when any suspicion exists in order to exclude car-
diac involvement during clinical follow-up [65,67,71-73,77].
This case also demonstrates that complete mastectomy and
other oncological and surgical procedures may result in a
favourable outcome for many years, but regular medical
lifelong follow-up is mandatory.
Katalinic et al. World Journal of Surgical Oncology 2013, 11:14 Page 9 of 10
http://www.wjso.com/content/11/1/14Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Abbreviations
[18F]FDG-PET/CT: 18F-fluorodeoxyglucose-positron-emission-tomography-
computed tomography; 2D-TEE: Two-dimensional transesophageal
echocardiography; 2D-TTE: Two-dimensional transthoracic echocardiography;
BM: Basement membrane; Ca 15–3: Carbohydrate antigen 15–3;
CEA: Carcinoembryonic antigen; CD133: Cluster of differentiation 133;
CD144: Cluster of differentiation 144; CD24: Cluster of differentiation 24;
CMF: Cyclophosphamide, methotrexate and fluorouracil; CSCs: Cancer steam
cells; CT: Computed tomography; ECG: Electrocardiogram/
electrocardiography; ECM: Extracellular matrices; ECOG PS: Eastern
cooperative cncology group performance status scale; EMT: Epithelial to
mesenchymal transition; ER: Estrogen receptor; Gy: Gray; HER-2/neu: Human
epidermal growth factor receptor 2; KPS: Karnofsky’s index of performance
status; MSCT: Multislice computed tomography; MMP: Matrix
metalloproteases; MRI: Magnetic resonance imaging; NF-κB: Nuclear factor
kappa-light-chain-enhancer of activated B cells; NPC: Nuclear pore complex;
Nup88: Nucleoporin 88; Nups: Nucleoporins; PET-MRI: Positron-emission
tomography-magnetic resonance imaging; PHD: Pathohistological diagnosis;
Rae1: Ribonucleic acid export 1; TGF-β: Transforming growth factor-β;
TNC: Tenascin C.
Competing interests
Each co-author certifies that s/he has no commercial association that might
pose a conflict of interest in connection with the submitted article.
Authors’ contributions
DK, RSP and SP carried out the study design and writing. II, IA and NN
participated in the data collection and interpretation and drafted the
manuscript. DK, RSP, FS and II participated in the design of the study and
the figure design. SP, DT, II, AJ and NN participated in the literature search
and helped to draft the manuscript. All authors have read and approved the
final manuscript.
Acknowledgements
We wish to express our sincere gratitude to Dr. Kristijan Nikolic, Ph.D. for
dedicated technical suggestions and artistic guidance in preparation of this
manuscript.
Author details
1Department of Oncology, University Hospital Centre (KBC Zagreb),
University of Zagreb School of Medicine, Kispaticeva 12, HR-10000, Zagreb,
Croatia. 2Department of Diagnostic and Interventional Radiology, University
Hospital Centre (KBC Zagreb), University of Zagreb School of Medicine,
Zagreb, Croatia. 3Department of Cardiovascular Diseases, University Hospital
Centre (KBC Zagreb), University of Zagreb School of Medicine, Zagreb,
Croatia. 4Department of Pulmonary Medicine, University Hospital Centre (KBC
Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia.
5Department of Pathology and Cytology, University Hospital Centre (KBC
Zagreb), University of Zagreb School of Medicine, Zagreb, Croatia.
6Department of Clinical Chemistry, University Hospital Centre “Sisters of
Charity”, University of Zagreb School of Medicine, Zagreb, Croatia.
Received: 1 August 2012 Accepted: 13 January 2013
Published: 23 January 2013
References
1. Tedeschi A: Beitrag zum Studium der Herzgeschwiilste. Prag Nmed
Wvchnschr 1893, 18:121.
2. Reynen K: Frequency of primary tumors of the heart. Am J Cardiol 1996,
77:107.
3. Burke A, Virmani R: Tumors of the Cardiovascular System, Atlas of Tumor
Pathology. Washington, DC: Armed Forces Institute of Pathology; 1996.
4. Klatt EC, Heitz DR: Cardiac metastases. Cancer 1990, 65:1456–1459.5. Prichard RW: Tumors of the heart. Review of the subject and report of
one hundred and fifty cases. Arch Pathol 1951, 51:98–128.
6. Chiles C, Woodard PK, Gutierrez FR, Link KM: Metastatic involvement of the
heart and pericardium: CT and MR imaging. Radiographics 2000,
20:1073–1103.
7. MacGee W: Metastatic and invasive tumours involving the heart in a
geriatric population: a necropsy study. Virchows Arch A Pathol Anat Histol
1991, 419:183–189.
8. Scott RW, Garvin CF: Tumors of the heart and pericardium. Am Heart J
1939, 17:431–436.
9. Bisel HF, Wróblewski F, LaDue JS: Incidence and clinical manifestations of
cardiac metastases. JAMA 1953, 153:712–715.
10. Young JM, Goldman IR: Tumor metastasis to the heart. Circulation 1954,
9:220–229.
11. Lockwood WB, Broghamer WL: The changing prevalence of secondary
cardiac neoplasms as related to cancer therapy. Cancer 1980,
45:2659–2662.
12. Lam KY, Dickens P, Chan ACL: Tumors of the heart. A 20-year experience
with a review of 12485 consecutive autopsies. Arch Pathol Lab Med 1993,
117:1027–1031.
13. Virmani R: Tumours metastatic to the heart and pericardium. In Atlas of
tumour pathology. Tumours of the heart and great vessels, 3rd Series Fascicle
16. Edited by Burke A, Virmani R. Washington, DC: AFIP; 1995:195–209.
14. McAllister HA Jr: Tumours of the heart and pericardium. In Cardiovascular
pathology. Volume 2. 2nd edition. Edited by Silver MD. New York, NY:
Churchill Livingstone; 1991:1297–1333.
15. Wenger NK: Pericardial disease in the elderly. Cardiovasc Clin 1992,
22:97–103.
16. Nakayama R, Yoneyama T, Takatani O, Kimura K: A study of metastatic
tumors to the heart, pericardium and great vessels. Jpn Heart J 1966,
7:227–234.
17. Abraham KP, Reddy V, Gattuso P: Neoplasms metastatic to the heart:
review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 1990,
3:195–198.
18. Bussani R, De-Giorgio F, Abbate A, Silvestri F: Cardiac metastases. J Clin
Pathol 2007, 60:27–34.
19. Gibbs P, Cebon JS, Calafiore P, Robinson WA: Cardiac metastases from
malignant melanoma. Cancer 1999, 85:78–84.
20. Paget S: The distribution of secondary growths in cancer of the breast.
Lancet 1889, 1:571–573.
21. Ewing J: A treatise of tumors. Philadelphia, PA: Saunders; 1928.
22. Suva LJ, Griffin RJ, Makhoul I: Mechanisms of bone metastases of breast
cancer. Endocr Relat Cancer 2009, 16:703–713.
23. Krug EL, Mjaatvedt CH, Markwald RR: Extracellular matrix from embryonic
myocardium elicits an early morphogenetic event in cardiac endothelial
differentiation. Dev Biol 1987, 120:348–355.
24. Hay ED: An overview of epithelio-mesenchymal transformation. Acta Anat
Basel 1995, 154:8–20.
25. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour
SL, Argast GM, Epstein DM, Haley JD: A systems view of epithelial-
mesenchymal transition signaling states. Clin Exp Metastasis 2010,
28:137–155.
26. Finger EC, Giaccia AJ: Hypoxia, inflammation, and the tumor
microenvironment in metastatic disease. Cancer Metastasis Rev 2010,
29:285–293.
27. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA: A switch from E-cadherin
to N-cadherin expression indicates epithelial to mesenchymal transition
and is of strong and independent importance for the progress of
prostate cancer. Clin Cancer Res 2007, 13:7003–7011.
28. Margulis A, Zhang W, Alt-Holland A, Crawford HC, Fusenig NE, Garlick JA: E-
cadherin suppressionaccelerates squamous cell carcinoma progression
in threedimensional, human tissue constructs. Cancer Res 2005,
65:1783–1791.
29. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA: Loss of E-
cadherin promotes metastasis via multiple downstream transcriptional
pathways. Cancer Res 2008, 68:3645–3654.
30. Yilmaz M, Christofori G: EMT, the cytoskeleton, and cancer cell invasion.
Cancer Metastasis Rev 2009, 28:15–33.
31. Dumont N, Bakin AV, Arteaga CL: Autocrine transforming growth factor-
beta signaling mediates Smadindependent motility in human cancer
cells. J Biol Chem 2003, 278:3275–3285.
Katalinic et al. World Journal of Surgical Oncology 2013, 11:14 Page 10 of 10
http://www.wjso.com/content/11/1/1432. Eckert MA, Yang J: Targeting invadopodia to block breast cancer
metastasis. Oncotarget 2011, 2:562–568.
33. Linder S: The matrix corroded: podosomes and invadopodia in
extracellular matrix degradation. Trends Cell Biol 2007, 17:107–117.
34. Oxmann D, Held-Feindt J, Stark AM, Hattermann K, Yoneda T, Meintlan R:
Endoglin expression in metastatic breast cancer cells enhances their
invasive phenotypeEndoglin enhances tumor invasion. Oncogene 2008,
27:3567–3575.
35. Hancox RA, Allen MD, Holliday DL, Edwards DR, Pennington CJ, Guttery DS,
Shaw JA, Walker RA, Pringle JH, Jones JL: Tumour-associated tenascin-C
isoforms promote breast cancer cell invasion and growth by matrix
metalloproteinase-dependent and independent mechanisms.
Breast Cancer Res 2009, 11:R24.
36. Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky
I, Abramovitch R: Heparanase promotes growth, angiogenesis and
survival of primary breast tumors. Int J Cancer 2006, 118:1609–1617.
37. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V: Endothelial
progenitor cells control the angiogenic switch in mouse lung metastasis.
Science 2008, 319:195–198.
38. Nolan DJ, Ciarrocchi A, Mellick AS, Jaggi JS, Bambino K, Gupta S, Heikamp E,
McDevitt MR, Scheinberg DA, Benezra R, Mittal V: Bone marrow-derived
endothelial progenitor cells are a major determinant of nascent tumor
neovascularization. Genes Dev 2007, 21:1546–1558.
39. Mellick AS, Plummer PN, Nolan DJ, Gao D, Bambino K, Hahn M, Catena R,
Turner V, McDonnell K, Benezra R, Brink R, Swarbrick A, Mittal V: Using the
transcription factor inhibitior of DNA binding 1 to selectively target
endothelial progenitor cells offers novel strategies to inhibit tumor
angiogenesis and growth. Cancer Res 2010, 70:7273–7282.
40. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk
A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C,
Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L,
Albertson DG, Waldman FM, Gray JW: Genomic and
transcriptionalaberrations linked to breast cancer pathophysiologies.
Cancer Cell 2006, 10:529–541.
41. Martinez N, Alonso A, Moragues MD, Ponton J, Schneider J: The nuclear
pore complex protein Nup88 is overexpressed in tumor cells. Cancer Res
1999, 59:5408–5411.
42. Gould VE, Martinez N, Orucevic A, Schneider J, Alonso A: A novel, nuclear
pore-associated, widely distributed molecule overexpressed in
oncogenesis and development. Am J Pathol 2000, 157:1605–1613.
43. Gould VE, Orucevic A, Zentgraf H, Gattuso P, Martinez N, Alonso A: Nup88
(karyoporin) in human malignant neoplasms and dysplasias: Correlations
of immunostaining of tissue sections, cytologic smears, and immunoblot
analysis. Hum Pathol 2002, 33:536–544.
44. Funasaka T, Wong RW: The role of nuclear pore complex in tumor
microenvironment and metastasis. Cancer Metastasis Rev 2011,
30:239–251.
45. Kline IK: Cardiac lymphatic involvement by metastatic tumor. Cancer
1972, 29:799–808.
46. Labib SB, Schick EC, Isner JM: Obstruction of right ventricular outflow tract
caused by intracavitary metastatic disease: Analysis of 14 cases. J Am Coll
Cardiol 1992, 19:1664–1668.
47. Dickens P, Poon CSP, Wat MS: Sudden death associated with solitary
intracavitary right atrial metastatic tumour deposit. Forensic Sci Int 1992,
57:169–173.
48. Kutalek SP, Panidis IP, Kotler MN, Mintz GS, Carver J, Ross JJ: Metastatic
tumors of the heart detected by two-dimensional echocardiography.
Am Heart J 1985, 109:343–349.
49. Johnson MH, Soulen RL: Echocardiography of cardiac metastases. Am J
Roentgenol 1983, 141:677–681.
50. Steffens TG, Mayer HS, Das SK: Echocardiographic diagnosis of a right
ventricular metastatic tumor. Arch Intern Med 1980, 140:122–123.
51. Reynen K, Köckeritz U, Strasser RH: Metastases to the heart. Ann Oncol
2004, 15:375–381.
52. Patek PR: The morphology of the lymphatics of the mammalian heart.
Am Heart J Anat 1939, 64:203–249.
53. Weiss L: Cascade spread of blood-borne metastases in solid and
non-solid cancers of humans. In Pulmonary metastasis. Edited by Weiss L,
Gilbert H. Boston: Hall; 1978:142–167.
54. Dalerba P, Clarke MF: Cancer stem cells and tumor metastasis: first steps
into uncharted territory. Cell Steam Cell 2007, 1:241–242.55. Ferrandina G, Petrillo M, Bonanno G, Scambia G: Targeting CD133 antigen
in cancer. Expert Opin Ther Targets 2009, 13:823–837.
56. McDermott SP, Wicha MS: Targeting breast cancer stem cells. Mol Oncol
2010, 4:404–419.
57. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R,
Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm
BE, Welm AL: Tumor grafts derived from women with breast cancer
authentically reflect tumor pathology, growth, metastasis and disease
outcomes. Nat Med 2011, 17:1514–1520.
58. Vici P, Sergi D, Pizzuti L, Vincenzoni C, Baiocco E, Mancini E, Lopez M, Vizza
E, Lauro LD: Biological progression of breast cancer and clinical
implications. Clin Ter 2011, 162:297–299.
59. Malaret GE, Aliaga P: Metastatic disease to the heart. Cancer 1968,
22:457–466.
60. Perchinsky MJ, Lichtenstein SV, Tyers GF: Primary cardiac tumors: forty
years’ experience with 71 patients. Cancer 1997, 79:1809–1815.
61. Vaitkus PT, Hermann HC, LeWinter MM: Treatment of malignant pericardial
effusion. JAMA 1994, 272:59–64.
62. Slater SR, Kroop IG, Zuckerman S: Constrictive pericarditis caused by
solitary metastatic carcinosis of the pericardium and complicated by
radiation fibrosis of mediastinum. Am Heart J 1952, 43:401–412.
63. Lamberta F, Nareff MJ, Schwab J: Metastatic carcinoma of pericardium.
Dis Chest 1951, 19:528–536.
64. Wolver S, Franklin RW, Abbate A: ST-segment elevation and new right-
bundle branch block: broadening the differential diagnosis. Int J Cardiol
2007, 114:247–248.
65. Cates CU, Virmani R, Vaughn WK, Robertson RM: Electrocardiographic
markers of cardiac metastasis. Am Heart J 1986, 112:1297–1303.
66. Rosenbaum F, Johnston FD, Alzamora VV: Persistenit displacement of RS-T
segmeat in case of metastatic tumor of heart. Am Heart J 1944,
27:667–675.
67. Siegel ML, Young AM: Electrocardiographic findings in tumors of heart,
with report of case. Am Heart J 1933, 8:682–690.
68. Hanfling SM: Metastatic cancer to the heart: review of the literature and
report of 127 cases. Circulation 1960, 22:474–483.
69. Sun JP, Asher CR, Xu Y, Huang V, Griffin BP, Stewart WJ, Novick AC, Thomas
JD: Inferior vena caval masses identified by echocardiography. Am J
Cardiol 1999, 84:613–615.
70. Hamada S, Nishimura T, Hayashida K, Uehara T: Intracardiac malignant
lymphoma detected by Gallium-67 Citrate and Thallium-201 Chloride.
J Nuc Med 1988, 29:1868–1870.
71. Johnson TRC, Becker CR, Wintersperger BJ, Herzog P, Lenhard MS, Reiser MF:
Detection of cardiac metastasis by positron-emission tomography-
computed tomography. Circulation 2005, 112:61–62.
72. Pichler BJ, Kolb A, Nägele T, Schlemmer HP: PET/MRI: paving the way for
the next generation of clinical multimodality imaging applications. J Nucl
Med 2010, 51:333–336.
73. Houck RC, Cooke JE, Gill EA: Live 3D echocardiography: a replacement for
traditional 2D echocardiography? AJR 2006, 187:1092–1106.
74. Catton C: The management of malignant cardiac tumours: clinical
considerations. Semin Diagn Pathol 2008, 25:69–75.
75. Ravikumar TS, Topulos GP, Anderson RW, Grage TB: Surgical resection for
isolated cardiac metastases. Arch Surg 1983, 118:117–120.
76. Poole GV, Meredith JW, Breyer RH, Mills SA: Surgical implications in
malignant cardiac disease. Ann Thorac Surg 1983, 36:484–491.
77. Ohnishi M, Niwayama H, Miyazawa Y, Kondo N, Imai H, Nishimoto Y,
Morooka N, Watanabe S, Masuda Y, Inagaki Y: Echocardiography in
patients with malignant metastatic neoplasms of the heart and great
vessels. J Cardiol 1990, 20:377–384.
78. Carrel T, Erdös G, Eberle B, Englberger L, Pfammatter JP, Schmidli J, Kadner
A, Stalder M: Surgical treatment of cardiac tumours - an overview and
presentation of interesting cases. Cardiovascular Medicine 2011,
14:242–257.
doi:10.1186/1477-7819-11-14
Cite this article as: Katalinic et al.: Symptomatic cardiac metastases of
breast cancer 27 years after mastectomy: a case report with literature
review - pathophysiology of molecular mechanisms and metastatic
pathways, clinical aspects, diagnostic procedures and treatment
modalities. World Journal of Surgical Oncology 2013 11:14.
